Clinical trial
Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene…
NCT05568719 · Pfizer, Industry · Recruiting
Key facts
| NCT number | NCT05568719 |
|---|---|
| Title | Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively |
| Official title | A PHASE 3, NON-INVESTIGATIONAL PRODUCT, MULTI COUNTRY COHORT STUDY TO DESCRIBE THE LONG-TERM SAFETY AND EFFECTIVENESS OF A PRIOR SINGLE-DOSE TREATMENT WITH INVESTIGATIVE GIROCTOCOGENE FITELPARVOVEC OR FIDANACOGENE ELAPARVOVEC IN PARTICIPANTS WITH HEMOPHILIA A OR HEMOPHILIA B, RESPECTIVELY |
| Lead sponsor | Pfizer, Industry |
| Status | Recruiting |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Hemophilia A, Hemophilia B |
| Intervention type | Diagnostic Test |
| Interventions | Testing of hepatic AAV Vector integration |
| Enrollment | 263 |
| Start date | Dec 28, 2022 |
| Primary completion | Feb 25, 2040 |
| Completion | Feb 25, 2040 |
| First posted | Oct 6, 2022 |
| Last update posted | Aug 14, 2025 |
| Countries | Australia, Turkey (Türkiye), United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: